<DOC>
	<DOCNO>NCT00318955</DOCNO>
	<brief_summary>The purpose study assess efficacy safety dexmedetomidine time extubation extubation , patient require postoperative sedation ICU .</brief_summary>
	<brief_title>Post-Marketing Clinical Study Assess Efficacy Safety Dexmedetomidine Post-Operative Patients</brief_title>
	<detailed_description>The study conduct phase IV post-marketing clinical study accordance approval condition dexmedetomidine hydrochloride Japan . The study compare use dexmedetomidine patient management time extubation sedative/ analgesic management , Comparison make use dexmedetomidine patient management group management perform dexmedetomidine group standard management perform propofol patient require postoperative sedation ICU The usefulness dexmedetomidine postextubation period also evaluate .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Patient legally acceptable representative ( acceptable Institutional Review Board/Ethics Committee ) sign date Informed Consent study fully explain . Patient male female ; least 20 year age . Patient condition American Society Anesthesiology ( ASA ) I III Class preoperatively Patient orally intubate anticipated require sedation mechanical ventilation minimum period 4 hour follow openheart surgery , coronary artery bypass grafting ( CABG ) , major vascular surgery If patient female child bear potential , nonpregnant , lactate Patient serious disturbance central nervous system ( disturbance consciousness ) . Patient undergone require intracranial surgery current hospitalization Patient require muscle relaxant drug admission ICU ( except endotracheal tube reinserted ) . Patient require epidural intrathecal administration analgesia/anesthesia surgery ICU stay . Patients propofol opioids contraindicate . Patient know suspected allergy medication might administer course study . Patient obese ( body mass index &gt; 35 ) Patient recently hospitalize drug overdose Patient alpha2 antagonist alpha2 agonist contraindicate Patient currently previously treat , within 30 day start study , alpha2 antagonist alpha2 receptor agonist . Patient participate another clinical study within 30 day prior admission ICU patient currently participate another clinical study . Patient diagnose severe symptom judge likely die within 24 hour . Patient consider unable undergo procedure require protocol . Patient excessive bleeding likely require reoperation . Patient ejection fraction &lt; 30 % . Patient , opinion investigator subinvestigator postmarketing clinical study , symptom factor may increase his/her risk result clinical study , may provide sufficient study data .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Dexmedetomidine , Sedation , Extubation , Phase 4</keyword>
</DOC>